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Abstract
Variations in levels of apolipoprotein E (ApoE) have been tied to the risk and progression of 
Alzheimer’s disease (AD). Our group has previously compared and contrasted the promoters of 
the mouse and human ApoE gene (APOE) promoter sequences and found notable similarities and 
significant differences that suggest the importance of the APOE promoter’s role in the human 
disease. We examine here three specific single-nucleotide polymorphisms within the human 
APOE promoter region, specifically at −491 (A/T), −427 (T/C), and at −219 (G/T) upstream from 
the +1 transcription start site. The −219 and −491 polymorphic variations have significant 
association with instance of AD, and −491AA has significant risk even when stratified for the 
APOEε4 allele. We also show significant effects on reporter gene expression in neuronal cell 
cultures, and, notably, these effects are modified by species origin of the cells. The −491 and −219 
polymorphisms may have an interactive effect in addition to any independent activity. DNA–
protein interactions differ between each polymorphic state. We propose SP1 and GATA as 
candidates for regulatory control of the −491 and −219 polymorphic sites. This work’s 
significance lies in drawing connection among APOE promoter polymorphisms’ associations with 
AD to functional promoter activity differences and specific changes in DNA–protein interactions 
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in cell culture-based assays. Taken together, these results suggest that APOE expression levels are 
a risk factor for AD irrespective of APOEε4 allele status.
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INTRODUCTION
Alzheimer’s disease (AD) is the leading cause of dementia among the elderly [Hebert et al., 
2003]. A known risk factor for AD is the apolipoprotein E (ApoE) ε4 genotype [Corder et 
al., 1993; Saunders et al., 1993; Lahiri, 2004a]. In addition to coding sequence 
polymorphisms, three promoter polymorphisms have been identified on the ApoE gene 
(APOE) with potential influence on sporadic AD [Bullido et al., 1998; Artiga et al., 1998b; 
Lambert et al., 2002]. These polymorphisms reside at −491 (rs449647, A/T), −427 
(rs769446, T/C), and −219 (TH1/E47cs, rs405509, G/T) [Lambert et al., 2002, 2004]. It has 
been reported that the −491AA genotype confers an independent risk for developing AD 
[Lambert et al., 2002, 2004], as has likewise been stated for the −219T allele [Lambert et al., 
2002, 2004], although the field is not unanimous, since reports that failed to find an AD 
association with the −491 [Thome et al., 1999; Toji et al., 1999] or the −219 [Zurutuza et al., 
2000; Tycko et al., 2004] loci are also in the literature. Meta-analysis of 38 studies indicated 
an AD-associated OR (95% CI) of 0.73 (0.64, 0.82) for the T allele at −491; meta-analysis 
of 13 studies showed an OR (95% CI) of 0.86 (0.68, 1.09) for the C allele at −427; and 
meta-analysis of 20 studies revealed an OR (95% CI) of 0.73 (0.68, 0.78) for the G allele at 
−217 [Bertram et al., 2007]. While important work has been done in characterizing effects of 
individual single nucleotide polymorphisms (SNPs) on promoter activity [Artiga et al., 
1998b; Ramos et al., 2005], evidence exists that these polymorphisms may function in vivo 
as haplogroups, with pathogenic influence beyond independent effects they may exert 
[Parra-Bonilla et al., 2003].
We have previously characterized the 5′-flanking regions of the APOE genes of mouse 
[Lahiri et al., 2002] and human [Du et al., 2005] and, more recently, determined important 
structural and functional differences between them, including the presence of functional 
promoter regulatory domains HuA (“human A”) through HuE and MoA (“mouse A”) 
through MoD [Maloney et al., 2007]. While the mouse sequence was determined to share 
homology at the −219 polymorphic site, no homology was found between human and mouse 
at either of the other two sites (−491 and −427). This notable structural difference between 
two species suggests an important role for the APOE promoter in the pathogenesis of AD. 
Therefore, we continued our work on the APOE promoter with the human sequence.
Healthy and AD-diagnosed subjects were genotyped for the APOE ε2/ε3/ε4 allele and for 
each of the two alleles at −491, −427, and −219. Statistically significant associations were 
observed with homozygosity for the A allele at the −491 promoter polymorphism and with 
homozygosity for the T allele at the −219 SNP. After stratification for presence of the ε4 
allele, the −491AA genotype retained significance as a risk factor for AD in the ε4-negative 
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population, whereas no such an association was detected in the ε4-positive group. Regarding 
the −219TT genotype, this same analysis revealed that the association was lost in both 
groups after stratification.
To investigate activity and potential interactions of the three APOE promoter SNPs, we 
constructed eight different clones containing 1.4 kb of the APOE 5′-flanking region. These 
clones included all currently known polymorphic variants at each of three locations fused to 
the chloramphenicol acetyltransferase (CAT) reporter gene. The clones were transfected into 
human SK–N–SH neuroblastoma (NB) and rat pheochromocytoma (PC12) neuronal cells 
and resulting reporter levels were analyzed. We determined that the −491 A/T polymorphism 
exerted independent effect on reporter protein levels in both NB and PC12 cells. The −219 
G/T polymorphism had significant independent effects in NB cells but not in PC12 cells. 
Multiple ANOVA analysis of data indicated a significant interaction between the effects 
exerted by the polymorphisms at −491 and −219 in PC12 cells but not in NB cells. The −427 
polymorphism did not have any significant effect on reporter gene product levels. In 
addition, each polymorphic state displayed differential DNA–protein interactions as revealed 
from electrophoretic mobility shift assay and Southwestern blotting experiments. Taken 
together, our work partially confirms the proposed existence [Parra-Bonilla et al., 2003] of a 
haplogroup of the −491 and −219 polymorphisms of the APOE promoter. Furthermore, the 
−491 polymorphism was confirmed as significantly altering APOE promoter activity 
independently of other polymorphisms in two cell lines from two different species while the 
−219 polymorphism only had this effect in human NB cells.
MATERIALS AND METHODS
Reagents
Unless otherwise specified, reagents were purchased from Sigma (St. Louis, MO) and were 
of “molecular biology” or “analytic” quality. Enzymes were purchased from Roche 
(Indianapolis, IN). Cell culture reagents were purchased from Invitrogen (Carlsbad, CA).
Cell Lines
Rat pheochromocytoma (PC12) and human SK–N–SH neuroblastoma (NB) cell cultures 
were acquired from ATCC and routinely cultured in our laboratory according to ATCC 
instructions [Ghosh et al., 2000]. Tissue culture reagents were obtained from Invitrogen.
Preparation of Nuclear Extracts
Nuclear extracts from NB and PC12 cell lines and from mouse brain tissue were obtained 
commercially (Active Motif, Carlsbad, CA).
Populations
The study population was recruited from the Alzheimer’s disease research center at Mayo 
Clinic, Rochester, MN. Samples from all subjects were collected under IRB approved 
protocols with informed consent signed by the individuals or next of kin. Patients were 
diagnosed with probable AD according to NINCDS–ADRDA criteria. DNA was extracted 
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from peripheral blood cells using standard protocols. All sample DNA’s were plated in 96-
well plates with cases and controls being randomly plated together.
The series comprised 310 sporadic late-onset AD cases (67% female, 15% autopsy 
confirmed) with mean age of 83.2±8.0 and mean age at onset of 77.6 ± 8.0. Controls for this 
cohort included 425 individuals (68% female; 5% autopsy confirmed) with mean age of 83.3 
± 7.1.
Genotyping of Patient DNA for APOε Promoter SNP Status
DNA extraction and APOE genotyping were performed according to published methods 
with minor modifications [Lahiri and Nurnberger, 1991; Crook et al., 1994; Lambert et al., 
1998; Artiga et al., 1998b]. A summary of primers, conditions, and genotyping details can 
be found in Table I.
Construction of APOε Promoter Polymorphism-CAT Reporter Fusion Clones
Genotyped DNA was isolated via PCR from human subjects using oligomers that inserted 
HindIII, KpnI, and XhoI linkers at the ends of a 1.4 kb APOE promoter/intron fragment 
(Fig. 1A). The fragment was inserted into the HindIII and XhoI sites of pBluescript SK (−) 
(Fig. 1B). Clones corresponding to six of eight possible SNP polymorphism combinations 
were constructed in this fashion. Two haplotypes (T/C/T and T/C/G) did not appear in our 
sample population (data not shown). These two clones were derived by site–directed 
mutagenesis of the corresponding −427T/−219T or −427T/−219 G haplotype clones using 
the Transformer site-directed mutagenesis kit (Clontech, Mountain View, CA). The 
pBluescript-backbone clones were digested with KpnI and XhoI and 1.4 kb APOE 
fragments were cloned into pGL3 (Promega) (Fig. 1C). Preliminary attempts to perform 
luciferase-based assays produced unacceptable noise due to well-to-well variation and cross 
talk from various neighboring wells. Therefore, the pGL3-backbone clones were digested 
with KpnI and XhoI. The 1.4 kb APOE promoter fragment band was purified from each and 
subcloned into the KpnI and XhoI sites of vector pCAT3Basic (Promega) to produce eight 
fusion clones, containing each possible permutation of the SNP variants, driving the CAT 
reporter coding sequence (Fig. 1D) to produce eight different polymorphic haplotype clones 
(Fig. 1E).
DNA Transfection of APOε Promoter Polymorphism-CAT Reporter Constructs in NB and 
PC12 Cell Cultures
NB and PC12 cell cultures were transfected with empty vector pCAT3Basic or one of eight 
polymorphic APOE promoter-CAT reporter constructs by Lipofectamine and the associated 
Plus Reagent (Invitrogen), as described previously [Ghosh et al., 2000]. Transfection was 
carried out in 2–3 × 106 cells per 60mm plate in triplicate, with 2.7 µg of CAT reporter clone 
plasmid DNA. To monitor transfection efficiency, cells were cotransfected with 0.3µg 
pSVβGAL (Promega) under the same conditions. Following transfection, cells were 
harvested, extracts prepared, protein concentration determined, CAT reporter protein levels 
were measured by enzyme-labeled immunosorbent assay (ELISA) and β-galactosidase (β-
GAL) activity was assayed colorimetrically [Ghosh et al., 2000]. Presence of β-GAL levels 
above background was taken as indicative of successful transfection.
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Reporter Gene Expression and Data Analysis
Activity of the reporter gene for all fusion clones was checked by measuring reporter protein 
levels by ELISA, using a commercial kit (Roche). Reporter protein level was adjusted to 
total protein in extract. Assays were done in linear range from three transfection 
experiments. Results from adjusted reporter gene activity were statistically analyzed with the 
SAS System 9.1 statistical analysis package (SAS Institute, Cary, NC) via three-way 
ANOVA followed by Waller–Duncan multiple range test or Student’s t-test.
Electrophoretic Mobility Shift Assay (EMSA) of APOε Polymorphisms
Oligomers reflecting the −491 A/T and −219 G/T SNPs, along with complementary 
oligomers, (Table II) were designed according to Artiga et al. [1998b] and commercially 
synthesized (Invitrogen) as single stranded oligomers. Oligomers were annealed with 
complements and labeled with [γ32P]-ATP (GE Healthcare, Piscataway, NJ) via 
polynucleotide kinase (Roche). All radiolabeled probes used in subsequent experiments 
were double stranded (ds). The assay was carried out with 10,000 cpm of probe (20–50 ng) 
and 10 µg of nuclear extracts. Nuclear protein extracts from NB and PC12 cells were 
incubated in 19 µl of EMSA binding buffer (10mM Tris–HCl, pH 7.5; 50mM NaCl; 0.5mM 
DTT, 5% glycerol; 0.05% Triton X-100; 100 µg/ml poly dI:dC) at 8°C for 15 min. In the 
“Competition-EMSA” assay, excess (150× molar concentration) unlabeled ds-oligomer was 
added and reactions were incubated at 8°C for 15 min. Radioactive probe was added (10,000 
CPM) and reactions further incubated at 8°C for 30 min. The samples were mixed with 
loading dye (50% glycerol, 1mM EDTA), and the products of the binding reaction were 
separated on a nondenaturing polyacrylamide gel (5%) in 1 × TGE buffer (50mM Tris-base, 
380mM glycine, and 2mM EDTA). The gel was dried and exposed to X-ray film with 
intensifying screen for fluorography at −70°C. Free unbound oligonucleotides ran at the 
bottom of the gel; different protein–DNA complexes were detected as mobility–retarded 
bands. Experiments were repeated with duplicate ds-oligomers obtained commercially (IDT 
Technology, Coralville, IA). Labeling of bands with Roman numerals was done according to 
migration rates of DNA-protein complexes.
Southwestern Blotting of Multiple Nuclear Extracts With Polymorphic ds-Oligomers
Nuclear extracts from NB and PC12 cells, 10 µg total protein, each, were run in duplicate 
sets on 10% SDS–PAGE in a MiniProtean gel apparatus (BioRad) as described previously 
[Lahiri et al., 1994]. Samples were transferred via tank blotting to 0.45 µm nitrocellulose 
membranes in 25mM of Tris–HCl, pH 7.4, 190mM glycine, 1mM EDTA and 0.01% SDS. 
Membrane was cut into two parts and each was probed individually by Southwestern 
blotting [Lahiri, 1998]. Briefly, proteins bound on the filter were renatured by incubation at 
4°C for 24 h in 15ml of 10mM HEPES, pH 7.9, 50mM NaCl, 0.1mM EDTA, 10mM MgCl2, 
1mM DTT, 10% glycerol and 5% milk powder (Carnation Non-fat). For DNA binding, the 
blocking solution was replaced by 15ml binding buffer (same composition as above except 
only 0.25% milk powder was used) with 10 µg poly dI:dC and 20 ng of each probe (specific 
activity 0.8 to 1.0 × 106 - CPM/ng) and was gently shaken at 4°C for 18 h. Filters were 
washed twice at room temperature in 50ml of the binding buffer (without probe and poly 
dI:dC) for 15 min each and exposed to X–ray film.
Maloney et al. Page 5
Am J Med Genet B Neuropsychiatr Genet. Author manuscript; available in PMC 2018 March 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
RESULTS
Genotype Frequencies of APOε Polymorphisms and AD Risk
The distribution of alleles and genotypes was consistent with that expected under Hardy–
Weinberg equilibrium (−491: P>0.5; −427: P>0.9; −219: P>0.2; coding region: P>0.6). 
Table III summarizes the results of the genetic analysis. As expected, the strongest 
association was found with the polymorphism at the coding region, possession of at least 
one copy of the ε4 allele significantly increased the risk for the disease (OR=4.29; CI95% = 
[3.16–5.82]). Additionally the reported protective effect of the ε2 allele was also seen 
(χ12 = 16.29, P = 5.43 × 10−5; OR = 0.40 CI95% = [0.25–0.63]; ε2 allele carriers vs. non-
carriers). In addition to this, statistically significant associations of similar magnitude were 
observed with homozygosity for the A allele at the −491 promoter polymorphism (χ12 = 7.57, 
P = 0.006; OR = 1.55 CI95% = [1.13–2.12]) and with homozygosity for the T allele at the 
−219 SNP (χ12 = 8.67, P = 0.003; OR = 1.64, CI95% = [1.18–2.18]).
After stratification for presence of the ε4 allele, the −491AA genotype was still a risk factor 
for AD in the ε4-negative population (χ12 = 4.62, P = 0.032; OR = 1.58, CI95% = [1.04–2.40]) 
whereas no such an association was still detected in the ε4-positive group. Regarding the 
−219TT genotype, this same analysis reveals that the association was lost in both groups 
after stratification.
Finally, logistic regression was used to detect interactions between the different 
polymorphisms, as well as age or sex. In this case, only the coding region polymorphism 
was still associated with the risk for AD (P < 10−4; OR = 1.90, CI95% = [1.64–2.22]).
Sequencing of APOε Promoter With SNP Regions
PCR of human genomic DNA samples with specific primers produced a 1.4 kb fragment 
(Fig. 1). Excepting for the specific locations of the three SNPs, DNA sequences derived 
within our sample were 100% homologous to GenBank sequence #M10065.
Reporter Expression Levels of APOε Promoter Polymorphisms in NB and PC12 Cells
To investigate effects of the three APOE promoter polymorphisms at −491, −427, and −219 
on promoter activity, NB and PC12 cell cultures were independently transfected with eight 
APOE promoter polymorphic clones, as described herein. Cells were also cotransfected with 
pSVβGAL to monitor transfection efficiency. Cells were collected and extracts used to 
measure total protein and for ELISA of reporter gene protein. Correlation analysis of raw 
data revealed that a strong confounding correlation (r = 0.628, P = 0.001) existed between 
ELISA signal of CAT reporter protein and activity of β-galactosidase (Table IV). Therefore, 
statistical analysis was continued with CAT reporter protein signal adjusted by total protein. 
In all cases, APOE promoter-reporter gene fusion clones had significantly higher reporter 
protein levels than did pCAT3Basic vector backbone. Analysis by each individual 
polymorphic site revealed that the −491 polymorphism drove significant independent 
difference in reporter protein levels in both cell lines (Fig. 2A and Fig. 3A). The −427 
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polymorphism (Fig. 2B and Fig 3B) showed no significant differences in activity between 
either allele. The −219 polymorphism had a significant difference of reporter levels in NB 
cells (Fig. 2C) but not in PC12 cells (Fig. 3C).
Multiple ANOVA (Table V and Table VI) indicated no significant interaction between any 
two-polymorphism effects in NB cells (Fig. 4). However, in PC12 cells (Fig. 5), there was a 
significant interaction between −491 and −219 (P < 0.0001). This interaction remained 
significant when ranked reporter protein levels were subject to ANOVA (Table VIB). The 
−219 variants had opposite (significant at kratio = 100) effects depending upon the particular 
−491 variant each was associated with (Fig. 5B). The −491A/−219G double polymorphism 
had significantly lower reporter protein levels than did −491A/−219T. On the other hand, 
−491T/−219G had significantly higher reporter protein levels than did −491T/−219T.
No significant three-way interaction appeared in NB cells (Fig. 6). A significant three-way 
interaction (P = 0.005) was detected in PC12 cells by multiple ANOVA (Fig. 7). However, 
this three-way interaction was weak at best (Fig. 7). While some individual polymorphic 
triads significantly differed from others (Fig. 7A), comparing the three–way interaction 
“sliced” according to the state of the −427 polymorphism showed little difference that 
specifically depended upon whether or not −427 was “C” or “T” (Fig. 6B and Fig 7B).
Electrophoretic Mobility Shift Assays (EMSA) of APOε Polymorphisms
Given that the −427 T/C polymorphism produced no significant results in our constitutive 
expression assay, it was excluded from EMSA analysis. Double-stranded oligomers 
corresponding to the −491 A/T and −219 G/T polymorphisms were obtained from two 
different sources and used to perform EMSA and competitive EMSA twice, as described 
herein. Reactions were performed with nuclear extracts from NB and PC12 cells. 
Competition was against unlabeled corresponding polymorphic ds-oligomer and against 
alternate polymorphic ds-oligomer for the same site in both NB and PC12 extracts. 
Additionally, in NB extracts, the −491A and T probes were competed against unlabeled 
−219G ds-oligomer, and the −219G and T probes were competed against unabeled −491A 
ds-oligomer, both as “negative controls” for the competition. It is likely that differences 
between DNA–protein interactions at the −491 polymorphic locus may be more quantitative 
in nature (altered affinity for the same transcription factors) than qualitative in NB nuclear 
extracts.
When NB nuclear extracts were probed (Fig. 8A), differences appeared between the −491A 
and −491T polymorphisms (lanes 1–8) and between the −219G and −219T polymorphisms 
(lanes 9–16). Both of the −491 variants had two DNA interaction bands (I, II) with NB 
nuclear extracts. However, interaction at band “I” was much stronger than at band “II” for 
−491A, while interaction was approximately equal between the two bands for −491T. 
Competition with 150× molar excess unlabeled ds-oligomers indicated that the −491A and T 
variants equally competed against radiolabeled −491A, while unlabeled −491T competed 
more efficiently against labeled −491T than did unlabeled −491A. There was also some 
limited competition of unlabeled −219G with the −491A probe. EMSA of the −219 
polymorphisms also showed differences between the two variants. When probing with 
−219G, three interactions (III, IV, VII) appeared. When probing with −219T, two different 
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interactions (V, VI) were present. Competition of labeled −219G with unlabeled −219G 
caused reduction in signal for all bands, but competition was incomplete. Competition with 
unlabeled −219T did not reduce any signal. Competition of labeled −219T with unlabeled 
−219T reduced the signal at “V” and “VI”. There was little to no signal reduction when 
competing with unlabeled −219G. Competition with unlabeled −491A had no effect on 
either labeled probe. Differences in DNA–protein interactions at the −291 locus are 
qualitative in NB nuclear extracts, indicating a change in specific transcription factor 
binding.
EMSA assay with the −491 probes and PC12 nuclear extracts (Fig. 8B, lanes 1–6) 
resembled the EMSA pattern found when NB nuclear extracts were probed with the same 
ds-oligomers (Fig. 8A). Two bands (I, II) appeared in uncompeted reactions (Fig. 8B, lanes 
1 and 4), although “II” was either very weak or absent with the −491A probe. Both −491 
unlabeled ds-oligomers strongly competed against labeled −491A (lanes 2 and 3), while 
competition was not as complete when unlabeled ds-oligomers were competed against 
labeled −491T (lanes 5 and 6). No specific signal was apparent when the −219G ds-oligomer 
was used to probe PC12 nuclear extracts, but when −219T was used to probe PC12 extracts 
(lanes 10–12), interactions appeared at “III” and “IV.” This interaction was blocked by 
unlabeled −219T but not by unlabeled −219G ds-oligomer. This indicates that a DNA–
protein interaction existed with PC12 nuclear extract to the −219T ds-oligomer, and it is 
specific to the “T” state of the polymorphism but is not present with the polymorphism’s 
“G” state in a rodent nuclear extract. Migration rates may be similar enough to consider “I” 
and “II” to be the same bands as “III” and “IV”, respectively.
Southwestern Blotting of APOε Polymorphisms
Nuclear extracts (10 µg) from PC12 and NB cells were subject to 10% SDS–PAGE and 
blotted to nitrocellulose. Uniformity of transfer was assessed by temporary staining with 
Ponceau S (Fig. 9A). The double–stranded oligomers that were used for EMSA were also 
used to probe the nitrocellulose membranes for Southwestern blotting. Assays were done in 
duplicate and figures are representative of results. Southwestern blotting with the −491A, 
−491T, −219G, and −219T probes produced at least one band with each probe in both PC12 
and NB nuclear extracts (Fig. 9B). Oligomers for the −491 A/T polymorphism had different 
binding patterns in PC12 and NB extracts, and these patterns differed between “A” and “T” 
variants (Fig. 9B). In PC12 extracts, the “A” variant bound a protein at approximately 60–70 
kDa, while the “T” variant lacked this binding. In contrast to the “A” SNP, “T” bound a 
protein that ran at approximately 30 kDa. In NB extracts, both −491 variants strongly 
interacted with a protein at approximately 125 kDa, and the “T” variant had an additional 
interaction at approximately 30 kDa.
The −219 G/T polymorphic ds-oligomers also had different binding patterns between PC12 
and NB nuclear extracts, and differences existed between “G” and “T” variants (Fig. 9B). 
Specifically, in PC12 extracts, the “G” variant had a distinct interaction at approximately 30 
kDa with a possible much weaker interaction at approximately 60–70 kDa, while the “T” 
variant interacted at 60–70 kDa. In NB nuclear extracts, both “G” and “T” variants 
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interacted with a protein at approximately 125 kDa, while the “G” variant had an additional 
interaction at approximately 30 kDa.
Alterations of Predicted TF Sites Around the APOε Polymorphisms
When sequences flanking each polymorphism were used to further probe the TransFac 
database, substituting minority polymorphic variant alleles at −491 (A → T), −427 (T → 
C), and −219 (G → T), several interesting predictions came to light. The 20 bp region 
between −481/−501 was predicted to gain likely binding sites for GATA-1, -2, and -3, while 
losing potential binding sites for p300, RXR-α, SP1, and SRY with the A → T 
polymorphism. The −417/−437 region was predicted to lose no putative binding sites while 
gaining AP-1, GC box, SP1, and T-Antigen binding sites with the T → C polymorphism. 
The −209/−229 region was predicted to lose Bcd, E47/Th1, GATA, LBP-1, and Prd sites 
while gaining a Cdx-1 site with the G → T polymorphism.
DISCUSSION
The ε4 APOE genotype is the strongest known genetic risk factor for AD. This genotype 
instills gain of function in the ApoE protein that corresponds to increased accumulation of 
Aβ peptide. Our underlying hypothesis is that increased expression of a lower risk factor 
genotype (e.g., ε3) can give analogous results to gain of function, upon the presumption that 
the function “gained” actually exists in the lower-risk phenotype, albeit operating at 
significantly lower efficiency. Association studies between ApoE levels and Aβ 
accumulation support this hypothesis [Lambert et al., 2005]. Selected APOE promoter 
SNPs, specifically occurring at −491 (A/T), −427 (T/C), and −219 (G/T) have been 
variously shown to potentially associate, independently or in tandem with each other, with 
incidence of AD [Belbin et al., 2007]. Meta-analysis has revealed associations between each 
of these sites and AD risk [Bertram et al., 2007]. Specific mechanisms of these SNPs have 
been previously investigated in cell culture and EMSA studies [Bullido et al., 1998; Artiga et 
al., 1998b]. These studies were done in hepatic cell lines and determined that the −491A 
polymorphic variant drove higher reporter expression than did −491T, but only in a single 
clone pair, not a full battery of possible variants. The previous studies also determined that 
the −219G variant drove greater reporter expression than did −219T, again only with a single 
clone pair.
In the population tested herein of 735 individuals, 310 of whom were diagnosed with 
sporadic AD, we determined that homozygosity for the −491A allele and for the −219T 
allele associated with significant risk (OR 1.55 and OR 1.64, respectively) of sporadic AD. 
After stratification for the presence of the ε4 allele, the −491AA genotype remained a risk 
factor for AD among non-ε4 subjects (OR 1.58).
We further investigated these SNPs’ responses in human neuroblastoma (NB) and rat 
neuronal (PC12) cells. In addition, we considered potential interactions between and among 
each polymorphic state. We have determined that the −491A variant independently produced 
greater levels of reporter protein than did the −491T variant in both NB and PC12 cell 
cultures. This corresponds to other studies that have linked the −491A variant to greater 
levels of ApoE in vivo [Laws et al., 2002] and in vitro [Artiga et al., 1998a] and to greater 
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risk of AD [Casadei et al., 1999; Lambert et al., 2002, 2004]. These studies, along with our 
own work, have led us to propose the model outlined in Figure 10. Briefly, our reporter 
assays determined that the −491A variant resulted in higher levels of reporter protein while 
−491T corresponded to lower reporter levels. In our own data, −491AA genotype 
corresponded to greater risk of AD when our sample was stratified for APOEε4 status. On 
the other hand, while we did observe a correspondence between −219 G/T CAT reporter 
fusion clone construction and reporter gene product levels, we did not observe a 
corresponding APOEε4-stratified AD risk (Fig. 11C–D). However, it should be noted that 
the −491AA genotype has also been associated with reduced levels of ApoE in vivo [Roks et 
al., 2002]. In addition, other studies have failed to find linkage between the −491 A/T SNP 
and effects on AD frequency [Roks et al., 1998; Toji et al., 1999].
In addition to effects in cell culture due to −491 A/T, our work herein has shown that the 
−219G variant independently produced greater levels of reporter protein in NB cells, but not 
in PC12 cells. The −219G polymorphism has been shown to associate with increased [Beyer 
et al., 2002] risk of AD in some populations, but other studies have shown that the T allele is 
associated with increased AD risk [Lambert et al., 2002, 2004]. In addition, multiple 
ANOVA of our data indicated interactive effects between the −491 A/T and −219 G/T 
alleles. A previous study by other workers has determined that the −491A/−219T 
“haplogroup” may confer AD risk [Lambert et al., 2004] and that these SNPs may work in 
vivo as a “haplogroup” more strongly than they do as independent alleles [Parra-Bonilla et 
al., 2003]. Such behavior would be similar to risk conferred by two promoter 
polymorphisms we have previously studied in the amyloid β precursor protein (APP) 
promoter [Lahiri, 2004b; Lahiri et al., 2005]. Combination of our reporter assay results with 
our analysis of potential changes in transcription factor binding sites at these two 
polymorphic sites suggests a model that may explain both our results and those noted by 
Lambert’s group (Fig. 11). Briefly, the −419A variant is predicted to have greater affinity for 
SP1 than does −491T, while −219G is predicted to have greater affinity for GATA family 
factors than does −219T. If the combination is −491A/−219T, SP1 binding drives greater 
expression of the APOE gene, resulting in greater risk of AD. On the other hand, our 
reporter assay determined nearly equal levels of reporter protein for both −491A/−219G and 
−419T/−219G. In this case, GATA factor(s) binding to the −219 site “override” the more 
distal site in regulation of the APOE gene promoter. When both sites are low affinity, as in 
−491T/−219T, then the APOE promoter would lack either additional stimulus, predicting 
lower levels of ApoE and reduced risk of AD. This model does not explain the behavior of 
−219 oligomers in EMSA with PC12 nuclear extracts. We have elsewhere investigated 
potentially important differences in human APOE promoter activity in human versus rodent 
cell cultures and extracts [Maloney et al., 2007]. As AD is a human disorder, we have given 
preference to results found with NB extracts in our model.
The SP1 transcription factor has been determined to be present in SK–N–SH cells (NB cells 
used herein) [Carrillo et al., 1999], and the GATA2, GATA3, GATA4, and GATA6 factors 
[Aoyama et al., 2005] are highly expressed in several neuroblastoma cell lines. Likewise, 
SP1 [Atkins et al., 2003; Nguyen et al., 2005] and GATA factors have been determined to be 
active in PC12 cells [Jia and Takimoto 2003; Lange-Dohna et al., 2003].
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Based on the functional and Southwestern blotting results, we suggest that loss of function 
in −491T may be due to loss of SP1 binding or altered affinity to an alternatively spliced 
form of SP1, which may be found in PC12 cells. This explanation, alone, would not suffice 
to explain activity changes for −219T due to loss of binding for another important TF of 30–
32 kDa (most likely GATA2 or 4). However, it has been previously shown that GATA1 acted 
in apparent cooperation with SP1 at the pyruvate kinase promoter and Tal-1 gene [Gregory 
et al., 1996] and that GATA4 and GATA6 interact directly with SP1 in modulation of tissue-
specific transcription of the cytochrome P450c17 gene [Fluck and Miller, 2004].
In PC12 nuclear extracts, the −491 “A” variant bound a protein at approximately 60–70 kDa, 
while the −491 “T” variant lacked this binding. This band may correspond to an alternatively 
spliced form of SP1 transcription factor, though SP1 is typically found to be a higher 
molecular weight protein (>110 kDa) [Thomas et al., 2007]. In contrast to the “A” variant, 
the “T” variant bound a protein that migrated at approximately 30 kDa, which may 
correspond to the predicted gain of a GATA binding site. In NB nuclear extracts, both −491 
variants strongly interacted with a protein at approximately 125 kDa, and the “T” variant had 
an additional interaction at approximately 30 kDa, again corresponding to a predicted gain 
of a GATA binding site. However, these binding experiments were not repeated with 
unlabeled −491 or −219 oligomers, leaving the specificity of these interactions unanswered.
We are, therefore, cognizant that our case in this paper for SP1 as the critical transcription 
factor in the activity of these APOE promoter polymorphisms is important but primarily 
circumstantial, based upon gel migration rates and predicted binding site affinity. The SP1 
transcription factor may be further implicated if evaluated in the broader context of AD-
related protein expression. We have previously determined that SP1 and APP co–localize in 
both mouse and monkey brain regions [Brock et al., 2008]. In addition, lifespan studies of 
SP1 and APP expression show that both genes’ mRNA levels tightly mirror each other in 
both mice and monkeys [Dosunmu et al., 2009].
The APOEε4 polymorphism is a gain-of-function variant, with chaperone activity that 
brings about plaque formation from oligomers of Aβ [Ma et al., 1994], however, gain-of-
function may be effectively mimicked by increase of “non-functional” variant levels if the 
“non-functional” variant actually has some small level of the function in question. We 
propose an explanation of the independent activity of the −491AA genotype in increasing 
AD risk in non-APOEε4 individuals. Specifically, the −491A allele is preferentially 
activated by the SP1 transcription factor over the −491T variant. This activation leads to 
increased levels of APOE gene transcription and of ApoE protein. When an individual’s 
APOE genotype lacks the ε4 allele, a “double dose” of increased APOE expression, via SP1 
activation of −491AA genotype, would still result in sufficiently greater amounts of APOE 
gene expression to partially “make up for” deficiency of APOEε4 chaperone activity. 
However, this “de facto gain-of-function” would still not be equivalent to the true gain-of-
function found in ApoE ε4 protein, which accounts for the lower, albeit still significant, 
increase in risk for AD found in −491AA individuals. There is increasing evidence that 
cholesterol plays a role in AD pathology, perhaps through its effects on amyloid deposition 
[Sparks et al., 1994, 2002; Pappolla et al., 2003; Sambamurti et al., 2004]. Furthermore, 
elevated low–density lipoprotein (LDL) levels correspond to greater brain amyloid β peptide 
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deposition [Kuo et al., 1998]. Likewise, study of an African population determined an 
association between higher levels of cholesterol and LDL and AD risk in individuals who 
lack the APOEε4 genotype [Hall et al., 2006]. In essence, we suggest that total levels of 
ApoE, and by extension, levels of LDL, and levels of circulating lipids in general, have an 
important influence on lifetime risk of developing AD for the majority of cases of the 
disease, specifically sporadic AD in individuals lacking the APOEε4 genotype.
This hypothesis would lead to parallel consideration of gene–environment interactions 
potentially influencing the effect of a promoter polymorphism. On the one hand, gene 
expression could be acutely perturbed due to inflammation, nutritional fluctuation, or stress. 
However, environment can also alter gene expression in a long-term fashion. One manner in 
which this can occur is by induction of a somatic epitype, persistent, non-heritable 
alterations in DNA methylation and/or oxidation in response to extrinsic factors, such as 
exposure to lead (Pb) [Lahiri and Maloney, 2006]. Pb exposure has further been determined 
to alter levels of SP1 in a latent early-life regulation (LEARn) fashion [Lahiri et al., 2007]. It 
should be noted that Pb exposure and APOE genotype have been found to interact in 
development of central nervous system toxicity [Stewart et al., 2002], and Pb was the 
specific agent determined to influence SP1 and APP levels in a LEARn fashion in two 
recently studied species, mice and monkeys [Basha et al., 2005; Wu et al., 2008]. This 
suggests a further possibility that variation in an SP1 site, such as found at the APOE−491 
A/T polymorphism, could be a factor in individual response to stressors such as Pb exposure 
potentially altering APOE levels, resulting in a similar effect to the Pb/APOE genotype 
interaction. This would present another avenue whereby variations in APOE gene promoter 
sequences would be influenced by environment, explaining the “incomplete” affect that the 
APOE promoter polymorphisms have been observed to have on incidence of AD.
Since the cell culture in the present work is carried out with PC12 and SK–N–SH cells, we 
briefly argue for their utility as CNS/neuronal cellular models. Our recent work [Ge et al., 
2004; Maloney et al., 2007] has shown distinct similarities of DNA–nuclear protein 
interactions for portions of the APP and APOE promoters, respectively, in PC12 and SK–N–
SH cell nuclear extracts versus both mouse and, importantly, post-mortem human brain cell 
nuclear extracts. In addition, several workers have shown that these cell lines express APP, 
synaptic proteins, and the secretases. However, even if these cells are accepted as suitable 
stand-ins for CNS neuronal cells, the valid issue can be raised that neurons do not typically 
express ApoE unless injured. We contend that pre-AD conditions are a type of stress or 
injury to neurons, which could cascade into full-blown AD, in part through altered 
expression of the APOE gene, thereby validating the use of neuronal cultures to study APOE 
expression in the context of AD etiology.
In addition, there is currently no complete model of AD available. Even most transgenic 
animal models do not use the “native” promoters of AD-associated genes. Instead, high-
throughput promoters, such as the promoter of the human prion protein PrP, are used to 
ensure certain and rapid development of AD-like symptoms in the animal.
Our study is also unique in that it does not solely measure effects of individual alleles on 
expression, but also potential interactions between and among the three polymorphic sites, 
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some of which interactions we have found to be significant by reporter expression assay. 
Likewise, most of the studies of these polymorphic sites have used a European population, 
while ours used a USA population, extending the size of the genetic pool from which all 
studies of these polymorphisms are drawn. It also examines allele effects at the multiple 
levels of population, gene expression, and DNA–protein interaction levels.
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FIG. 1. 
Construction of expression-cassette clones containing three single–nucleotide 
polymorphisms in the APOε promoter sequence. A: Schematic diagram of a 1.4 kb PCR 
fragment of the APOε gene (small arrows indicate locations of PCR primers), including the 
5′-UTR and 1 kb of promoter, and a fragment of the first intron of the gene, as produced by 
PCR from human genomic DNA samples. Three single-nucleotide polymorphic sites 
[Bullido et al., 1998; Artiga et al., 1998b; Lambert et al., 2002] are indicated (−491, −427, 
and −219) in relationship to the transcription start site (+1). An active NF-κB site [Du et al., 
2005] and promoter activity domains [Maloney et al., 2007] (HuA-“human A”-through 
HuE) are also indicated. B: The 1.4 kb fragment was cloned into the KpnI and XhoI sites of 
pBluescript SK (−). C: The pBluescript-backbone clone was digested with KpnI and XhoI, 
and the 1.4 kb APOε fragment was subcloned into the KpnI/XhoI sites of pGL3Basic. D: 
The pGL3Basic-backbone clone was digested with KpnI and XhoI, and the 1.4 kb APOε 
fragment was cloned into the KpnI/XhoI sites of pCAT3Basic. E: Eight different haplotype 
APOε promoter-CAT expression gene clones were generated and subsequently used for 
DNA transfection studies.
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FIG. 2. 
Effects of individual single–nucleotide polymorphism on reporter levels in NB cells. APOε 
promoter polymorphism-CAT reporter fusion clones were transfected into NB cells as 
described. Cell lysates were extracted and reporter protein levels measured by ELISA. Data 
were grouped in three ways, according to the state of each individual polymorphism. All 
APOε-derived clones drove reporter levels significantly higher than empty pCAT3-basic 
backbone. “N” refers to either variant at the non-specified polymorphism locus. The top 
portion of each figure schematically depicts locations of SNPs with respect to the APOε 
promoter. A: −491 A/T polymorphism. Each state was significantly different from the other. 
B: −427 T/C polymorphism. Neither state differed significantly from the other. C: −219 G/T 
polymorphism. Each state was significantly different from the other.
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FIG. 3. 
Effects of individual single-nucleotide polymorphism on reporter levels in PC12 cells. APOε 
promoter polymorphism-CAT reporter fusion clones were transfected into PC12 cells as 
described. Cell lysates were extracted and reporter levels measured by ELISA. Data were 
grouped in three ways, according to the state of each individual polymorphism. All APOε-
derived clones drove reporter protein levels significantly higher than empty pCAT3-basic 
backbone. “N” refers to either variant at the non-specified polymorphism locus. The top 
portion of each figure schematically depicts locations of SNPs with respect to the APOε 
promoter. A: −491 A/T polymorphism. Each state was significantly different from the other. 
B,C: −427 T/C and −219 G/T polymorphisms. Neither state within either polymorphism 
differed significantly from the other.
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FIG. 4. 
Interactions between any two of three APOε promoter polymorphisms in NB cells. Reporter 
level activity data from APOε promoter polymorphism-CAT reporter fusion clones 
transfected in NB cells were combined according to any two polymorphic sites. “N” refers 
to either variant at the non-specified polymorphism locus. A: Activity of clones arranged 
according to specific −491/−219 combination. Combinations that share statistical symbols 
do not significantly differ from each other. B: Activity of clones arranged according to 
specific −491/−427 combination. Combinations that share statistical symbols do not 
significantly differ from each other. C: Activity of clones arranged according to specific 
−427/−219 combination. Combinations that share statistical symbols do not significantly 
differ from each other.
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FIG. 5. 
Interactions between any two of three APOε promoter polymorphisms in PC12 cells. 
Reporter level activity data from APOε promoter polymorphism-CAT reporter fusion clones 
were combined according to any two polymorphic sites. “N” refers to either variant at the 
non-specified polymorphism locus. A: Activity of clones arranged according to specific 
−491/−219 combination. Combinations that share statistical symbols do not significantly 
differ from each other. B: Activity of clones arranged according to specific −491/−427 
combination. Combinations that share statistical symbols do not significantly differ from 
each other. C: Activity of clones arranged according to specific −427/−219 combination. 
Combinations that share statistical symbols do not significantly differ from each other.
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FIG. 6. 
Reporter protein levels of APOε promoter polymorphism triplet-CAT fusion clones in NB 
cells. A: Reporter level activity data from APOε promoter polymorphism-CAT reporter 
fusion clones were combined according to all three polymorphic sites. Data were analyzed 
by Waller–Duncan multiple range test as described in the text. Individual combination of 
each of two states for three polymorphic sites (eight total combinations) is shown. 
Combinations that share statistical symbols do not significantly differ from each other. B: 
“Slice” of reporter protein levels according to state of −427 polymorphic site. Similarity of 
response “curves” between states indicates that effect of the −427 polymorphism on the 
overall system is very low.
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FIG. 7. 
Reporter protein levels of APOε promoter polymorphism triplet-CAT reporter fusion clones 
in PC12 cells. A: Reporter level activity data from APOε promoter polymorphism-CAT 
reporter fusion clones were combined according to all three polymorphic sites. Data were 
analyzed by Waller–Duncan multiple range test as described. Each individual combination 
of states for three polymorphic sites (eight total combinations) is shown. Combinations that 
share statistical symbols do not significantly differ from each other. B: “Slice” of reporter 
protein levels according to state of −427 polymorphic site. Similarity of response “curves” 
between states indicates that effect of the −427 polymorphism on the overall system is very 
low, despite a “significant” three-way interaction ANOVA result.
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FIG. 8. 
Electrophoretic mobility shift assay (EMSA) of APOε promoter polymorphic ds-oligomers 
(A) EMSA in NB nuclear extracts. Polymorphic ds-oligomers were synthesized and labeled 
with [γ32P]-ATP as described in the text. ds-Oligomers were incubated with nuclear extracts 
from NB cells as described in the text. Reactions were run on native 5% TGE (Tris/Glycine/
EDTA)–PAG (polyacrylamide gel) electrophoresis, gel was dried, and subject to 
radiofluorography. Bands corresponding to DNA–protein interactions are labeled according 
to blotted protein migration rate; unbound probe ran at bottom of gel (not shown). B: EMSA 
in PC12 nuclear extracts. Polymorphic ds-oligomers were synthesized and labeled with 
[γ32P]-ATP. ds-Oligomers were incubated with nuclear extracts from PC12 cells as 
described in the text. Reactions were run on native 5% TGE–PAG, gel was dried, and subject 
to radiofluorography. EMSA bands are indicated.
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FIG. 9. 
Southwestern blots of APOε promoter polymorphic ds-oligomers in NB and PC12 cell 
nuclear extracts. Nuclear proteins from NB (lanes 3, 4, 7, and 8) and PC12 (lanes 1, 2, 5, and 
6) cells were separated via denaturing 10% SDS–PAGE and blotted to nitrocellulose. A: 
Blots were stained with Ponceau S and photographed. B: Blots were probed with [γ32P]-
ATP labeled oligomers for APOε promoter polymorphisms −491A (lanes 1 and 3), −491T 
(lanes 2 and 4), −219G (lanes 5 and 7), and −219T (lanes 6 and 8) under renaturing 
conditions as described in the text. Blots were exposed to X-ray film for fluorography.
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FIG. 10. 
Schematic representation of APOε promoter polymorphism activity. Diagrams represent 
relative activities of each of two APOε promoter polymorphisms (−491 A/T and −219 G/T) 
found to be active in our reporter gene assay. A: Activity of −491 A/T polymorphism in NB 
and PC12 cells. Taken together, the −491A clones showed significantly higher expression of 
reporter gene product than did −491T clones. This corresponds with our observation that 
−491AA genotype correlates with increased risk of AD. B: Activity of −219 G/T 
polymorphism in NB cells. Taken together, the −219G clones showed significantly higher 
expression of reporter gene product than did −219T clones. However, associated risk for AD 
was not independent at the −219 G/T polymorphism when stratified for APOεε4 status.
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FIG. 11. 
Interaction of −491 A/T and −219 G/T polymorphisms. The −219 G/T polymorphism did 
not bring about significant changes in reporter gene product levels in PC12 cells. However, 
multiple ANOVA revealed interaction between −491 A/T and −219 G/T. Examination of the 
data revealed that the −219T variant appears to “intensify” the effects of −491A versus T 
while −219G “mutes” this effect. When compared to putative loss or gain of transcription 
factor binding sites, the (A) presence of an SP1 site and absence of a GATA site 
corresponded to greatest reporter levels. This corresponded to increased AD risk in 
“haplogroup” analysis performed by other laboratories [Parra-Bonilla et al., 2003]. The 
presence of a GATA site, regardless of whether an SP1 site was (B) present or (C) absent 
corresponded to intermediate levels of CAT reporter product. D: When both sites were 
absent, CAT reporter levels were lowest in our study.
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TABLE II
Oligomers for Electrophoretic Mobility Shift and Southwestern Assays
Oligomer Sequence
−491A-F 5′-GCTGGTCTCAAACTCCTGACCTTAA-3′
−491A-R 5′-TTAAGGTCAGGAGTTTGAGACCAGC-3′
−491T-F 5′-GCTGGTCTCAATCTCCTGACCTTAA-3′
−491T-R 5′-TTAAGGTCAGGAGATTGAGACCAGC-3′
−219G-F 5′-GGAGGAGGGTGTCTGGATTACTGGGCG-3′
−219G-R 5′-CGCCCAGTAATCCAGACACCCTCCTCC-3′
−219T-F 5′-GGAGGAGGGTGTCTGTATTACTGGGCG-3′
−219T-R 5′-CGCCCAGTAATACAGACACCCTCCTCC-3′
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TABLE IV
Correlation of Raw CAT Reporter Protein ELISA, β-GAL Activity, and Total Cellular Protein in Transient 
DNA Transfection Assays
CAT ELISA Total protein β-GAL Activity
A. Correlations in NB cells
CAT ELISA 1
na
Total protein 0.23355 1
P = 0.2721 na
β-GAL activity 0.54456 −0.40755 1
P = 0.0059 P = 0.0481 na
B. Correlations in PC12 cells
CAT ELISA 1
na
Total protein −0.27462 1
P = 0.1941 na
β-GAL activity 0.77672 −0.63253 1
P < .0001 P = 0.0009 na
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